Loading viewer...
investor_presentation
Format: PDF investor_presentation
Teva Pharmaceutical and Sanofi announced an exclusive collaboration for TEV-574, an anti-TL1A therapeutic, in October 2023. The presentation outlines strategic rationale, clinical program updates, and financial overview of this transformative partnership aimed at advancing innovative immunology treatments.
investor_presentation
37 Pages
investor_presentation
23 Pages
Solvay
iAnthus Capital Holdings Investor Presentation — September 2019
investor_presentationinvestor_presentation
26 Pages
iAnthus Capital Holdings, Inc.